EFFICACY AND COST OF DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HCV INFECTION AMONG HCV MONOINFECTED AND HIV/HCV COINFECTED PATIENTS IN REAL LIFE SETTING
CP-044
APPROPRIATENESS OF ALBUMIN TREATMENT IN NON-CRITICAL AND NON - ONCOHAEMATOLOGICAL HOSPITALISED PATIENTS
CP-183
EFFECTIVENESS AND SAFETY OF BIOLOGICAL THERAPY OPTIMISATION IN CHRONIC PLAQUE PSORIASIS
CP-217
EVALUATION OF ANTIVIRAL PRESCRIPTION FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION
CP-210
THE ADDED ROLE OF PHARMACEUTICAL INTERVENTION ON HEPATITIS C VIRUS DIRECT ANTIVIRAL AGENT TREATMENT: A SINGLE CENTRE OBSERVATIONAL PROSPECTIVE COHORT ANALYSIS
CP-207
ANALYSIS OF FREQUENCY OF UNDERDOSING IN OBESE PATIENTS TREATED WITH VANCOMYCIN
CP-201
POLYPHARMACY AND POTENTIALLY INAPPROPRIATE MEDICATIONS IN GERIATRIC OUTPATIENTS
CP-196
THE IMPACT OF SOCIAL STATUS ON THE FINANCIAL EQUILIBRIUM OF ENDOVASCULAR TREATMENT OF INTRACRANIAL ANEURYSMS IN PUBLIC HOSPITAL
CP-141
VENOUS THROMBOEMBOLISM PROPHYLAXIS ADEQUACY OF MEDICAL PATIENTS: CROSS SECTIONAL STUDY
CP-122
PEMBROLIZUMAB AND INMUNE MEDIATED NEPHRITIS: A CASE REPORT
CP-121
SEVERE HEPATOTOXICITY INDUCED BY CERITINIB IN A METASTATIC NON-SMALL-CELL LUNG CANCER PATIENT: A CASE RESPORT
CP-097
TOCILIZUMAB FOR THE TREATMENT OF A CASTLEMAN’S DISEASE PAEDIATRIC PATIENT: A CASE REPORT
CP-054
CLINICAL PREDICTORS OF RESPONSE TO TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
CP-050
MEDICATION DISCREPANCIES AT THE TIME OF ADMISSION TO AND TRANSFER FROM THE INTENSIVE CARE UNIT (ICU) AND THE ROLE OF A CLINICAL PHARMACIST
CP-048
EARLY RECOVERY AFTER CAESAREAN SECTION AND EVALUATION OF CARBETOCIN
